arrow
C

Carey K. Anders

duke cancer center
H指数:66
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Addition of tucatinib to trastuzumab/pertuzumab after local therapy for isolated intracranial progression in HER2-positive metastatic breast cancer: primary results of the phase II BRIDGET trial☆

在HER2阳性转移性乳腺癌孤立性颅内进展后,在局部治疗后添加tucatinib至trastuzumab/pertuzumab的治疗:BRIDGET II期试验的初步结果<a class="anchor anchor-primary" href="#fn1" name="bfn1" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fn1"><span class="anchor-text-container"><span class="anchor-text"><sup>☆</sup></span></span></a>

2026-11-130
OA
RMTC-10 DEFINING SYMPTOMATIC VERSUS ASYMPTOMATIC BRAIN METASTASES FOR CLINICAL TRIAL ELIGIBILITY: A DELPHI CONSENSUS INITIATIVE

RMTC-10 定义有症状与无症状脑转移用于临床试验入组资格:一项德尔菲共识倡议

2026-08-070
OA
Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer

定量HER2组织与血浆分析可预测曲妥珠单抗德鲁克替康对乳腺癌的活性

2026-03-130
OAAI
The evolving landscape of brain metastasis: volume II

脑转移的演变景观: 第二卷

2025-12-020
OAAI
Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative

颅内转移瘤:神经肿瘤学会和临床肿瘤学会协作的呼吁与共识

2025-10-060
OAAI
Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases

基于tucatinib的疗法在HER2阳性转移性乳腺癌患者中的真实世界治疗模式与临床结局:两项全国性行政健康索赔数据库的分析

2025-08-060
OAAI
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium

乳腺癌管理中的争议与关键知识空白专家观点:第一届弥合乳腺癌知识空白研讨会的会议录

2025-04-080
PRE
Consortium for Intracranial Metastasis Academic Research (CIMARa): Global interdisciplinary collaborations to improve outcomes of patient with brain metastases

脑转移瘤学术研究联盟(CIMARa):全球跨学科合作以改善脑转移瘤患者预后

2025-03-040
OA
Pregnancy and pregnancy outcomes after adolescent and young adult cancer in the AYA horizon study
2025-02-010
PRE
Secondary BRain metastases prevention after Isolated intracranial progression on trastuzumab/pertuzumab or T-DM1 in pts with aDvanced human epidermal Growth factor receptor 2+brEast cancer with addition of Tucatinib (BRIDGET)
2024-05-020
PRE
Impact of HER2 expression dynamics on the realworld activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
2024-05-020
PRE